FDA Approves Turalio for Joint Tumors
On Friday, the U.S. Food and Drug Administration (FDA) approved the first-ever drug, called Pexidartinib (Turalio), for the treatment of tenosynovial giant cell tumors (TGCT). However, it will be available with black box warning mentioning its potential to affect the liver.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed